NCT05369780 is a NA clinical trial of Hydrolyzed Collagen Peptide in Pain, Joint, sponsored by Sel Sanayi Urunleri Ticaret ve Pazarlama A.S..

Who is sponsoring NCT05369780?

NCT05369780 is sponsored by Sel Sanayi Urunleri Ticaret ve Pazarlama A.S..

What drugs are being tested in NCT05369780?

Interventions in NCT05369780: Hydrolyzed Collagen Peptide.

What condition does NCT05369780 study?

NCT05369780 studies Pain, Joint.

Is NCT05369780 still recruiting?

NCT05369780 is currently status unknown. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT05369780

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis

Status unknown NA Last updated 11 May 2022

What this trial tests

NA trial testing Hydrolyzed Collagen Peptide in Pain, Joint in 160 participants. Status unknown.

Timeline

15 May 2022

Primary endpoint
15 May 2023

15 May 2023

Quick facts

Lead sponsor	Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	160
Start date	15 May 2022
Primary completion	15 May 2023
Estimated completion	15 May 2023

Drugs / interventions tested

Hydrolyzed Collagen Peptide

Conditions studied

Pain, Joint — all drugs for Pain, Joint →

Sponsor

Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.

Who can join

Adults 45 to 60, any sex, with Pain, Joint. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effectiveness of Hydrolyzed collagen peptides on joint pain, stiffness and physical function in adults with osteoarthritis who have complaints on knee joints together with hip and ankles. The assessment of improvements on volunteers' quality of life, and safety and tolerability of the product is the other objective of this placebo-controlled, randomized study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of the Efficacy and Safety of CollaSel PRO<sup>®</sup> Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Demir-Dora D, Tuna S, Kurtoglu ED, Gursoy S, et al · · 2025 · PMID 40507417 · DOI 10.3390/jcm14113655

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05369780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05369780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing